medigraphic.com
ISSN 0016-3813 (Print)

2014, Number S2

<< Back Next >>

Gac Med Mex 2014; 150 (S2)

Respuesta a la quimioterapia neoadyuvante (QTneo) según los subtipos intrínsecos determinados por inmunohistoquímica (IHQ) en pacientes con cáncer de mama

Ruvalcaba LE, Elizabeth Barreda ZE, García ON, Morales VF, Bautista PV, Maffuz AA, Rodríguez CS

Language: Spanish
References: 34
Page: 161-170
PDF size: 296.91 Kb.


ABSTRACT

Introduction: Breast cancer is heterogeneous, with different responses to NC even within similar histology and stages. Objective: To evaluate clinical/pathological response to NC according to different tumor subtypes in Mexican breast cancer patients. Patients and methods: Retrospective study of patients with breast cancer stages II-III, and complete immunohistochemistry (IHC), such as hormonal receptors HER2 and Ki67, treated with NC and surgery. Descriptive and comparative analyses between different intrinsic subtypes were performed. Results: A total of 117 patients were included with 48.6 ± 10.6 years of age, stage II (24%), and III (76%). We identified 20 (17.1%) cases of luminal A, 37 (31.6%) luminal B HER2–, 13 (11.1%) luminal B HER2+, 12 (10.3%) HER2+, and 35 (29.9%) triple negative. Clinical complete response (tumor and lymph nodes) in luminal A was 10%, in luminal B HER2– 10.8%, luminal B HER2+ 15.4%, HER2+ 25%, and in triple negative 14.3%. Conservative surgeries were done in 9 (7.7%) patients. There is a weak positive association between Ki67 expression and tumor clinical response. Pathological complete response occurred in 8 (6.83%) cases, being more frequent in luminal B HER2+ patients (23%). Conclusions: Pathological complete responses were more often in luminal B HER2+ cases.


REFERENCES

  1. Vara-Salazar E, Suárez-López L, Ángeles-Llerenas A, Torres-Mejía G, Lazcano-Ponce E. Tendencias de la mortalidad por cáncer de mama en México, 1980-2009. Salud Pub Mex. 2011;53(5):385-93.

  2. Estadísticas a propósito del día mundial contra el cáncer. Datos nacionales. México, D.F., 4 de febrero de 2010. [Internet] Consultado el 5 de septiembre de 2010. Disponible en: http://www.inegi.org.mx/inegi/ contenidos/espanol/prensa/Contenidos/estadisticas/2010/cancer10. doc.

  3. Cárdenas-Sánchez J, Bargalló-Rocha E, Erazo-Valle A, Maafs-Molina E, Poitevin-Chacón A. Consenso Nacional sobre Diagnóstico y Tratamiento del Cáncer Mamario. 5.a revisión. Colima; 2013. [Internet] Consultado el 30 de junio de 2014. Disponible en: http://www.consensocancermamario. com/documentos/FOLLETO_CONSENSO_DE_CANCER_DE_ MAMA_5aRev2013.PDF.

  4. Montero AJ, Diaz-Montero CM, Deutsch YE, et al. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat. 2012;132(1):215-23.

  5. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678-85.

  6. Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. Molecular classification of estrogen receptor-positive/ Luminal breast cancers. Adv Anat Pathol. 2012;19(1):39-53.

  7. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.

  8. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-23.

  9. Tan BK, Tan LK, Yu K, et al. Clinical validation of a customized multiple signature microarray for breast cancer. Clin Cancer Res. 2008; 14(2):461-9.

  10. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-47.

  11. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-23.

  12. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003;100(18):10393-8.

  13. Chen XS, Wu JY, Huang OU, et al. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. Oncol Rep. 2010;23(5):1213-20.

  14. Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology. 2010;79(5-6):324-30.

  15. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of Breast Cancer by Immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLOS medicine. 2010;7(5):e1000279.

  16. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907-22.

  17. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Ca Inst. 2000;92(3):205-16.

  18. Van Persijn EL, Van Meerten H, Gelderblom J, Bloem L. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol. 2010;20:1456-67.

  19. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, et al. Triple-negative breast cancer in Hispanic patients. Cancer. 2011;117(16):3658-69.

  20. Rodríguez-Cuevas S, Macias CG, Franceschi D, Labastida S. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer. 2001;91(4):863-8.

  21. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of Tumours of the Breast. 4.a ed. En: WHO Classification of Tumours. Volumen 4. IARC WHO Classification of Tumours, n.o 4, 2012. p. 22-23.

  22. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-34.

  23. Fasching PA, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486.

  24. Zhou B, Yang DQ, Xie F. Biological markers as predictive factors of response to neoadjuvant taxanes and anthacycline chemotherapy in breast carcinoma. Chin Med J. 2008;121(5):387-91.

  25. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cáncer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342-54.

  26. Bhargava R, Beriwal S, Dabbs DJ, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer. 2010;116(6):1431-9.

  27. Straver ME, Rutgers EJ, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17(9):2411-8.

  28. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377-84.

  29. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28(12):2024-31.

  30. Burguete-Vera JJ, Mainero-Ratchleous F, Vargas-Solano JM, Burgos- Portillo I, Bernechea-Miranda A, Uriban-Aguilar I. Respuesta clínica y patológica a la quimioterapia neoadyuvante en pacientes con cáncer de mama etapa clínica III en el Hospital de Gineco-obstetricia n.o 4 «Luis Castelazo Ayala». GAMO. 2008;7(2):52-5.

  31. Ruvalcaba-Limón E, Robles-Vidal C, Poitevin-Chacón A, Chávez-Mac- Gregor M, Gamboa-Vignolle C, Vilar-Compte D. Complications after breast cancer surgery in patients treated with concomitant preoperative chemoradiation: a case-control analysis. Breast Cancer Res Treat. 2006;95(2):147-52.

  32. Alvarado-Miranda A, Arrieta O, Gamboa-Vignolle C, et al. Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer. Radiat Oncol. 2009;4:24.[Internet] Disponible en: http://www.ro-journal.com/content/pdf/1748-717X-4-24.pdf.

  33. Bautista-Hernández Y, Rubio-Nava O, Pérez Villanueva H, González-Avendaño JJ, Portillo-Reyes J, Luján-Castilla PJ. Resultados en el tratamiento de cáncer de mama localmente avanzado en la Unidad de Oncología del Hospital General de México OD. GAMO. 2012;11(1):5-17.

  34. Uribe JR, Hernández CA, Menolascino F, et al. Clasificación molecular del cáncer de mama y su correlación clínica. Rev Venez Oncol. 2010;22 (2):109-16.




2020     |     www.medigraphic.com